Discovery - University of Dundee - Online Publications

Library & Learning Centre

Long-acting β-agonist prescribing in people with asthma in primary care

Standard

Long-acting β-agonist prescribing in people with asthma in primary care. / Morales, Daniel R; Jackson, Cathy; Fielding, Shona; Guthrie, Bruce.

In: Thorax, Vol. 68, No. 2, 01.02.2013, p. 192-194.

Research output: Contribution to journalArticle

Harvard

Morales, DR, Jackson, C, Fielding, S & Guthrie, B 2013, 'Long-acting β-agonist prescribing in people with asthma in primary care' Thorax, vol 68, no. 2, pp. 192-194., 10.1136/thoraxjnl-2012-202071

APA

Morales, D. R., Jackson, C., Fielding, S., & Guthrie, B. (2013). Long-acting β-agonist prescribing in people with asthma in primary care. Thorax, 68(2), 192-194. 10.1136/thoraxjnl-2012-202071

Vancouver

Morales DR, Jackson C, Fielding S, Guthrie B. Long-acting β-agonist prescribing in people with asthma in primary care. Thorax. 2013 Feb 1;68(2):192-194. Available from: 10.1136/thoraxjnl-2012-202071

Author

Morales, Daniel R; Jackson, Cathy; Fielding, Shona; Guthrie, Bruce / Long-acting β-agonist prescribing in people with asthma in primary care.

In: Thorax, Vol. 68, No. 2, 01.02.2013, p. 192-194.

Research output: Contribution to journalArticle

Bibtex - Download

@article{2c45d39c61804a84a9270104f9434430,
title = "Long-acting β-agonist prescribing in people with asthma in primary care",
author = "Morales, {Daniel R} and Cathy Jackson and Shona Fielding and Bruce Guthrie",
note = "Copyright 2013 Elsevier B.V., All rights reserved.",
year = "2013",
doi = "10.1136/thoraxjnl-2012-202071",
volume = "68",
number = "2",
pages = "192--194",
journal = "Thorax",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - Long-acting β-agonist prescribing in people with asthma in primary care

A1 - Morales,Daniel R

A1 - Jackson,Cathy

A1 - Fielding,Shona

A1 - Guthrie,Bruce

AU - Morales,Daniel R

AU - Jackson,Cathy

AU - Fielding,Shona

AU - Guthrie,Bruce

PY - 2013/2/1

Y1 - 2013/2/1

N2 - Long-acting ß2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

AB - Long-acting ß2-agonist (LABA) monotherapy is contraindicated in asthma following reports of serious adverse events. Anonymised Scottish health data were used to determine the prevalence of LABA prescribing and LABA monotherapy (sustained and episodic) in asthma during 2006. Of 73 486 asthma patients identified, 5592 (7.6%; 95% CI 7.4% to 7.8%) were prescribed LABAs as a separate inhaler of which 991 patients had LABA monotherapy (17.7% (95% CI 16.7% to 18.7%) of patients at risk). Asthma reviews were associated with reductions in sustained (OR 0.44; 95% CI 0.32 to 0.61) but not episodic monotherapy (OR 1.16; 95% CI 0.85 to 1.57). These findings support recent changes in UK asthma guidelines recommending LABAs in fixed-dose combination inhalers.

UR - http://www.scopus.com/inward/record.url?scp=84872686039&partnerID=8YFLogxK

U2 - 10.1136/thoraxjnl-2012-202071

DO - 10.1136/thoraxjnl-2012-202071

M1 - Article

JO - Thorax

JF - Thorax

IS - 2

VL - 68

SP - 192

EP - 194

ER -

Documents

Library & Learning Centre

Contact | Accessibility | Policy